{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-017292","form_type":"8-K","ticker":"TGTX","cik":"0001001316","company_name":"TG THERAPEUTICS, INC.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:49.136353+00:00","generated_at":"2026-06-21T22:00:28.973697+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"TG Therapeutics reports Q3 net loss of $35.8M; ublituximab PDUFA set for Dec 28, 2022","bullets":["Net loss of $35.8M for Q3 2022 vs $85.6M in Q3 2021; nine-month net loss of $145.3M.","Cash, equivalents and securities totaled $197.7M as of Sept 30, 2022; funding expected into 2024.","R&D expense fell to $20.8M from $52.0M; SG&A decreased to $14.3M from $34.9M YoY.","Ublituximab BLA for relapsing MS has PDUFA goal date of December 28, 2022; commercial prep ongoing.","Company plans to launch ublituximab early 2023 if FDA approves."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-017292","json":"https://secwatch.observer/filing/0001558370-22-017292.json","markdown":"https://secwatch.observer/filing/0001558370-22-017292.md","text":"https://secwatch.observer/filing/0001558370-22-017292.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/tgtx-20221110x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:00:28.973697+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"071538c1fabba4cacc2113a868743a24fc52d45f","claim":"TG THERAPEUTICS, INC. reported three months ended September 30, 2022 results: net income $35.8 million.","evidence_excerpt":"Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Net income","value":"$35.8 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"e935f2a6fb4b555e9bd5e0c5562e6704e8990a00","claim":"TG THERAPEUTICS, INC. reported nine months ended September 30, 2022 results: net income $145.3 million.","evidence_excerpt":"Net loss was $35.8 million and $145.3 million for the three and nine months ended September 30, 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1001316/000155837022017292/0001558370-22-017292-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Net income","value":"$145.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}